SELECT A SPEAKER TO VIEW THEIR BIO.
Welcome and Introduction
Breaking News: New HCV Clinical Advances
What Will it Take to Achieve Global Hepatitis Elimination by 2030: Lessons from Country Experiences
Enhancing Access to HCV Treatment in Prisons: Lessons from the Australian Model
Recruiting and Training PCPs in Rural California - One County at a Time
Role of Civil Society in Hepatitis Elimination: WHA Campaign from the Primary Care & Patient Advocate Perspective
TABLE DISCUSSION: Clinical Challenges and HCV Elimination Strategies
Jordan Feld MD, MPH
R. Phelan Chair in Translational Liver Research Research Director, Toronto Centre for Liver Disease Toronto General Hospital, University Health Network Scientist, Sandra Rotman Centre for Global Health Toronto, Ontario, Canada
Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Currently, Dr. Feld is clinician-scientist based at the Toronto General Hospital, Toronto Centre for Liver Disease and the McLaughlin-Rotman Centre for Global Health.
Research Support: AbbVie, Gilead, Merck, Janssen. Consultant: AbbVie Gilead, Contravir, Medimmune, and Merck.
Norah Terrault, MD, MPH
Professor of Medicine Director, Viral Hepatitis Center Department of Gastroenterology/Hepatology University of California, San Francisco San Francisco, California, USA
Dr. Norah Terrault is a Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.
Research Support: AbbVie, ADMA Biologics, Allergan Pharmaceuticals, Bristol Myers Squibb, Gilead Sciences, and Merck. Consultant: ADMA Biologics and Dova Pharmaceuticals. Continuing Medical Education: Focus Medical Communications and Practice Point Communications Educational Material Development: CCO Hepatitis.
Alex Thompson, MBBS (hons), PhD, FRACP
Director of Gastroenterology, St. Vincentâ€™s Hospital Melbourne Professorial Fellow, University of Melbourne Department of Gastroenterology, SVHM Victoria, Australia
Alex Thompson is Professor-Director of Gastroenterology at St. Vincent's Hospital Melbourne (University of Melbourne) Director of State-wide Hepatitis Program in Victorian prisons. His research interests include models of care for hepatitis with a focus on elimination and the identification of host and viral determinants of the natural history and treatment outcomes of hepatitis B and C viruses. Alex was involved in the discovery of IL28B polymorphism as a predictor of treatment outcome in HCV. He has published widely in journals including Nature, Gastroenterology, Hepatology, Gut and Journal of Hepatology.
Research Support: AbbVie, Gilead Sciences, and Merck. Consultant: AbbVie, BMS, Eisai, Gilead Sciences, and Merck. Speakers Bureau: AbbVie, BMS, Gilead Sciences, Merck, and Roche Diagnostics.
Nick Walsh, MD, PhD
Regional Advisor for Viral Hepatitis at the Pan American Health Organization WHO Regional Office for the Americas Washington, District of Columbia
Nick Walsh is a medical doctor with qualifications through the Royal Australasian College of Physicians, and a clinical background in the screening, care and treatment of hepatitis, in particular B and C, and HIV in Australia and Cambodia. He also has substantial experience in a number of other clinical domains including addiction medicine, infectious diseases, emergency and internal medicine and has worked extensively in indigenous communities in northern Australia. He has a public health background with particular experience in HIV and viral hepatitis in the Asia Pacific and Australia, and has consulted since 2006 to the World Health Organization including from 2009 to WHO Headquarter's HIV department, Global Hepatitis Programme and Mental Health and Substance Abuse. He has contributed to the development of global guidance on viral hepatitis B and C and opioid overdose. He holds a PhD in epidemiology from Monash University.
He lived and worked in public health and clinic medicine in Vietnam in 2002 and in Cambodia from 2008 â€“ 2014. From 2014 he was the focal point for viral hepatitis, within the HIV, Hepatitis and STI unit in Communicable Diseases at the World Health Organization Regional Office for the Western Pacific in Manila, Philippines. In early 2017 he moved to The Pan American Health Organization/ WHO Regional Office for the Americas as Regional Advisor for the 35 countries across the Americas and Caribbean.
Dr. Walsh has no relationships to disclose
Su Wang, MD, MPH, FACP
Medical Director, Center for Asian Health Saint Barnabas Medical Center Florham Park, NJ, USA WHA Executive Board Member
Su Wang, MD, MPH is the Medical Director of the Center for Asian Health, a comprehensive medical practice serving the Asian community in New Jersey. Dr. Wang practices internal medicine and leads the Center's growth, outreach and grant programs as part of Saint Barnabas Medical Center (SBMC) and the RWJBH network. She also serves as the Medical Director of the newly created Saint Barnabas Liver Center. Previously, she directed the Hepatitis B Program at Charles B. Wang Community Health Center in New York City, where she led its nationally recognized programs in primary care-based hepatitis B care and community based participatory research.
Dr. Wang is on the Executive Board for the World Hepatitis Alliance, an international partner with the World Health Organization (WHO) representing viral hepatitis patients and global efforts to eliminate viral hepatitis by 2030, a goal adopted by the WHO countries. She is currently Co-Chair of the New Jersey Hepatitis B Coalition and involved with Hepatitis B United, a national coalition representing community efforts in the U.S. She has served as primary investigator for hepatitis B screening and linkage-to-care grants sponsored by the CDC and other funders, and is the lead for the FOCUS Hepatitis B/C screening program at the SBMC Emergency Department.
She received her medical degree from the University of Miami as part of the Honors Program in Medicine and obtained her Masters of Public Health from Johns Hopkins School of Public Health. She completed a combined Internal Medicine and Pediatric residency at Georgetown University Hospital and then served as an Epidemic Intelligence Service officer for the Centers for Disease Control and Prevention (CDC) at the Food and Drug Administration.
Research Support: Gilead Sciences.